Operations: The company's revenue from the Blood Safety segment is $169.98 million.

Market Cap: $318.71M

Cerus Corporation, with a market cap of US$318.71 million, has shown steady revenue growth from its Blood Safety segment, reaching US$169.98 million. Despite being unprofitable and having a negative return on equity, Cerus has reduced losses over the past five years by 15.1% annually and forecasts further revenue growth of 10.96% per year. The company recently secured a significant six-year agreement with BARDA worth up to $248 million to advance its INTERCEPT RBC system in the U.S., which could bolster future prospects if regulatory milestones are achieved successfully. However, shareholders have faced dilution and increased debt levels recently.

• Jump into the full analysis health report here for a deeper understanding of Cerus.

• Examine Cerus' earnings growth report to understand how analysts expect it to perform.

Expensify

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Expensify, Inc. offers a cloud-based expense management software platform catering to individuals, corporations, small and midsized businesses, and enterprises globally, with a market cap of approximately $161.74 million.

Operations: The company's revenue is primarily generated from its Internet Software & Services segment, totaling $138.53 million.

Market Cap: $161.74M

Expensify, Inc., with a market cap of US$161.74 million, operates in the cloud-based expense management sector and faces challenges typical of penny stocks. The company reported declining sales for the first half of 2024 at US$66.82 million, down from US$78.99 million the previous year, alongside a reduced net loss of US$6.55 million compared to US$17.25 million last year. Despite being unprofitable and experiencing shareholder dilution by 6.1%, Expensify maintains a strong cash position exceeding its total debt and short-term liabilities, providing a cash runway for over three years amidst significant insider selling recently noted.

• Take a closer look at Expensify's potential here in our financial health report.

• Assess Expensify's future earnings estimates with our detailed growth reports.

Where To Now?

• Take a closer look at our US Penny Stocks list of 756 companies by clicking here.

• Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools.

• Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free.

Ready To Venture Into Other Investment Styles?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.

• Jump on the AI train with fast growing tech companies forging a new era of innovation.

• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NasdaqCM:ALVR NasdaqGM:CERS and NasdaqGS:EXFY.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]